# RElugolix VErsus LeUprolide Cardiac Trial

> **NCT05320406** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Emory University** · enrollment: 94 (actual)

## Conditions studied

- Biochemically Recurrent Prostate Carcinoma
- Localized Prostate Carcinoma
- Stage I Prostate Cancer AJCC v8
- Stage II Prostate Cancer AJCC v8
- Stage IIA Prostate Cancer AJCC v8
- Stage IIB Prostate Cancer AJCC v8
- Stage IIC Prostate Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
- Stage IIIA Prostate Cancer AJCC v8
- Stage IIIB Prostate Cancer AJCC v8
- Stage IIIC Prostate Cancer AJCC v8

## Interventions

- **RADIATION:** Radiation therapy
- **DRUG:** Leuprolide
- **DRUG:** Relugolix

## Key facts

- **NCT ID:** NCT05320406
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-06
- **Primary completion:** 2025-01-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05320406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05320406, "RElugolix VErsus LeUprolide Cardiac Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05320406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*